<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Orphanet J Rare Dis</journal-id>
      <journal-id journal-id-type="iso-abbrev">Orphanet J Rare Dis</journal-id>
      <journal-title-group>
        <journal-title>Orphanet Journal of Rare Diseases</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1750-1172</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26399329</article-id>
      <article-id pub-id-type="pmc">4581011</article-id>
      <article-id pub-id-type="publisher-id">342</article-id>
      <article-id pub-id-type="doi">10.1186/s13023-015-0342-6</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Ketogenic diet in a patient with congenital hyperinsulinism: a novel approach to prevent brain damage</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Maiorana</surname>
            <given-names>Arianna</given-names>
          </name>
          <address>
            <phone>+390668592275</phone>
            <email>arianna.maiorana@opbg.net</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Manganozzi</surname>
            <given-names>Lucilla</given-names>
          </name>
          <address>
            <email>lucilla.manganozzi@hotmail.it</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Barbetti</surname>
            <given-names>Fabrizio</given-names>
          </name>
          <address>
            <email>fabrizio.barbetti@uniroma2.it</email>
          </address>
          <xref ref-type="aff" rid="Aff2"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bernabei</surname>
            <given-names>Silvia</given-names>
          </name>
          <address>
            <email>silviamaria.bernabei@opbg.net</email>
          </address>
          <xref ref-type="aff" rid="Aff3"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gallo</surname>
            <given-names>Giorgia</given-names>
          </name>
          <address>
            <email>giorgia.gallo@opbg.net</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Cusmai</surname>
            <given-names>Raffaella</given-names>
          </name>
          <address>
            <email>raffaella.cusmai@opbg.net</email>
          </address>
          <xref ref-type="aff" rid="Aff4"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Caviglia</surname>
            <given-names>Stefania</given-names>
          </name>
          <address>
            <email>stefania.caviglia@opbg.net</email>
          </address>
          <xref ref-type="aff" rid="Aff5"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dionisi-Vici</surname>
            <given-names>Carlo</given-names>
          </name>
          <address>
            <email>carlo.dionisivici@opbg.net</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><label/>Metabolic Unit, Department of Pediatric Medicine, Bambino Ges&#xF9; Children&#x2019;s Hospital, piazza S. Onofrio 4, 00165 Rome, Italy </aff>
        <aff id="Aff2"><label/>Department of Experimental Medicine, University of Tor Vergata and Bambino Ges&#xF9; Children&#x2019;s Hospital, Rome, Italy </aff>
        <aff id="Aff3"><label/>Clinical Nutrition, Gastroenterology Department, Bambino Ges&#xF9; Children&#x2019;s Hospital, Rome, Italy </aff>
        <aff id="Aff4"><label/>Neurology, Neuroscience Department, Bambino Ges&#xF9; Children&#x2019;s Hospital, Rome, Italy </aff>
        <aff id="Aff5"><label/>Psychology Unit, Neuroscience Department, Bambino Ges&#xF9; Children&#x2019;s Hospital, Rome, Italy </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>9</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>24</day>
        <month>9</month>
        <year>2015</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2015</year>
      </pub-date>
      <volume>10</volume>
      <elocation-id>120</elocation-id>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>6</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>10</day>
          <month>9</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Maiorana et al. 2015</copyright-statement>
        <license license-type="OpenAccess">
          <license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>Congenital hyperinsulinism (CHI) is the most frequent cause of hypoglycemia in children. In addition to increased peripheral glucose utilization, dysregulated insulin secretion induces profound hypoglycemia and neuroglycopenia by inhibiting glycogenolysis, gluconeogenesis and lipolysis. This results in the shortage of all cerebral energy substrates (glucose, lactate and ketones), and can lead to severe neurological sequelae. Patients with CHI unresponsive to medical treatment can be subjected to near-total pancreatectomy with increased risk of secondary diabetes. Ketogenic diet (KD), by reproducing a fasting-like condition in which body fuel mainly derives from beta-oxidation, is intended to provide alternative cerebral substrates such ketone bodies. We took advantage of known protective effect of KD on neuronal damage associated with GLUT1 deficiency, a disorder of impaired glucose transport across the blood-brain barrier, and administered KD in a patient with drug-unresponsive CHI, with the aim of providing to neurons an energy source alternative to glucose.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>A child with drug-resistant, long-standing CHI caused by a spontaneous <italic>GCK</italic> activating mutation (p.Val455Met) suffered from epilepsy and showed neurodevelopmental abnormalities. After attempting various therapeutic regimes without success, near-total pancreatectomy was suggested to parents, who asked for other options. Therefore, we proposed KD in combination with insulin-suppressing drugs.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>We administered KD for 2&#xA0;years. Soon after the first six months, the patient was free of epileptic crises, presented normalization of EEG, and showed a marked recover in psychological development and quality of life.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>KD could represent an effective treatment to support brain function in selected cases of CHI.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Congenital hyperinsulinism</kwd>
        <kwd>Ketogenic diet</kwd>
        <kwd>Hypoglycemia</kwd>
        <kwd>Epilepsy</kwd>
        <kwd>Neurodevelopment</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2015</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Background</title>
      <p>Congenital hyperinsulinism (CHI) is the most frequent cause of hypoglycemia in children [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Mutations that affect insulin secretion regulation by the three main classes of energy substrates, i.e. glucose, aminoacids, and free fatty acids (FFA) [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>], can cause CHI that requires rapid diagnosis and treatment to limit/avoid neuronal damage [<xref ref-type="bibr" rid="CR4">4</xref>] and the irreversible neurological sequelae consequent to prolonged, severe hypoglycemia. Neurons in the superficial layers of cerebral cortex and hippocampus are those preferentially affected by lack of glucose, followed by neurons in basal ganglia and thalamus [<xref ref-type="bibr" rid="CR5">5</xref>]. However, mild, recurrent hypoglycemia can cause hippocampal synaptic dysfunction even in absence of neuronal damage [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. These experimental findings explain why memory, learning, intelligence and attention are the cognitive domains most vulnerable to hypoglycemia in children with type 1 diabetes [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Although glucose is the main energy source for neurons, human brain can also utilize ketone bodies from FFA, lactate, pyruvate, glycerol and some aminoacids, as alternative substrate [<xref ref-type="bibr" rid="CR10">10</xref>]. The protective effect of ketone bodies on hypoglycemia-induced neuronal damage has been demonstrated in animal studies [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>] and also in patients with type 1 diabetes, in whom the ingestion of medium-chain triglycerides prevented the cognitive deficit induced by hypoglycemia by elevating blood levels of 3-hydroxybutyrate [<xref ref-type="bibr" rid="CR13">13</xref>]. Ketogenic diet (KD), which provides FFA as alternative fuel to carbohydrates for neuronal energy metabolism, has therefore a strong potential neuroprotective effect. The main indication of KD in children is the treatment of refractory epilepsy, but it is also the causal therapy of GLUT1 deficiency, a metabolic disorder characterized by epilepsy, developmental delay and movement disorders [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. In GLUT1 deficiency, neuroglycopenia that ensues as consequence of the impaired glucose transport across the blood-brain barrier [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>] is effectively improved by KD that provides ketone bodies as alternative energy source for the brain. In CHI, excessive insulin secretion not only induces severe neuroglycopenia, but also halts, by inhibiting gluconeogenesis, glycogenolysis and lipolysis, the use of other metabolic pathways that provide energetic substrates to the neurons. Other inherited metabolic diseases, such as mitochondrial fatty oxidation defects, share the same neurological risk of hypoglycemia because of lack of ketones [<xref ref-type="bibr" rid="CR16">16</xref>]. Therefore, developing brain of patients with CHI is more vulnerable than other forms of hypoglycemia. Based on the similarities of brain metabolism perturbation shared by GLUT1 deficiency and CHI, we attempted to tackle neuroglycopenic symptoms and outcome by administering KD in a patient with severe, drug-resistant form of CHI.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Methods</title>
      <p>We report a case of severe persistent hyperinsulinemic hypoglycemia due to a &#x201C;de novo&#x201D; mutation in <italic>GCK</italic>. The girl presented with hypoglycemic seizures since the first years of life. Family history was positive for type 2 diabetes. From the age of 2&#xA0;years, she was admitted to the hospital for recurrent episodes of severe hypoglycemia (up to 1.5&#xA0;mmol/L, normal value 3.9&#x2013;5.5&#xA0;mmol/L [<xref ref-type="bibr" rid="CR17">17</xref>]) associated to cold sweating, seizures and hypotonia. At the age of 3&#xA0;years laboratory tests were performed and showed hypoglycemia with hyperinsulinemia (blood glucose 1.95&#x2013;2.3&#xA0;mmol/L; plasma insulin 5.5&#x2013;10.2 &#x3BC;UI/ml). EEG showed abnormal waves in the left hemisphere and epileptogenic abnormalities, and treatment with valproate was started. Genetic investigation for <italic>ABCC8</italic> and <italic>KNCJ11</italic> performed elsewhere was negative. At 9&#xA0;years of age the patient was referred to our hospital, and the heterozygous p.Val455Met mutation was found at <italic>GCK</italic> gene sequencing [<xref ref-type="bibr" rid="CR18">18</xref>]; parents showed wild type <italic>GCK</italic> sequence. At admission, the child was receiving a combination of high-dose diazoxide (12&#xA0;mg/kg/day) and octreotide (15 &#x3BC;g/kg/day), with no apparent clinical response. Previously, a trial with nifedipine (up to 0.75&#xA0;mg/kg/day) had been attempted without benefit. We gradually increased octreotide to 50 &#x3BC;g/kg/day in combination with diazoxide (10&#xA0;mg/kg/day) but observed persistence of hypoglycemia and epilepsy. A further association with slow-release carbohydrate to drugs did not elicit any clinical improvement, and the patient continued to present hypoglycemic episodes (0.5&#x2013;1.6&#xA0;mmol/L), seizures and absence epilepsy regardless of glycemic values, that required frequent hospitalizations. Despite a mild improvement of neurologic symptoms after switch from valproate therapy to ethosuccimide, absence epilepsy and evident EEG abnormalities persisted, even in the intercritical phases; her intellectual function was borderline. Furthermore, at the age of 10&#xA0;years the patient quickly gained 11.5&#xA0;kg within 12&#xA0;months, becoming mildly obese (BMI z-score: &gt;97<sup>th</sup> centile). Overall, her quality of life was very poor. The lack of response to drug therapy with risk of permanent and severe brain sequelae made us to consider a near-total pancreatectomy, that was discussed with parents with the warning of no guarantee to achieve normoglycemia and of the increased hazard of secondary diabetes. At parents&#x2019; request to avoid surgery, we then proposed a trial with KD, explaining that it was aimed to prevent neuroglycopenic epilepsy and to improve neurological status by providing ketone bodies as an alternative energy source for neurons, as seen in GLUT1 deficiency. Consent was obtained from patient and parents after full explanation of the objective. With the new dietary regimen we provided 85&#xA0;% of energy from lipids, 8&#xA0;% from proteins, and 7&#xA0;% from glucose of a normocaloric diet divided in 5 meals. Determination of blood ketones (Nova StatStrips&#xAE; Glucose Ketone Meter, Nova Medical, Menarini Diagnostics, Florence, Italy) in the morning (after overnight fast of 10&#x2013;12&#xA0;h) and in the evening (after dinner) was utilized as guidance to establish the ratio of lipids: proteins plus carbohydrates. The ratio was progressively increased every three months from 1.5:1 to 3:1 during the first year of KD in order to obtain a blood ketone concentration close to 4&#xA0;mmol/L [<xref ref-type="bibr" rid="CR19">19</xref>]. First assessment of the KD outcome was performed as inpatient; auxological evaluation, hepatic and renal function, plasma glucose, insulin, lactate, FFA, blood ketones and lipid profile, along with renal tubular function and abdomen ultrasound were assessed every 6&#xA0;months. Follow-up included 96 to 120-h long continue glucose monitoring (CGM- ipro2, Medtronic; data analysis by MiniMed software, Medtronic, MiniMed, Northridge, CA, USA&#xAE;) [<xref ref-type="bibr" rid="CR20">20</xref>] with EEG performed simultaneously. Weschsler Intelligence scale for Children (WISC III: third edition) and Vineland Adaptive Behavior Scale were serially administered to evaluate cognitive and adaptive abilities.</p>
    </sec>
    <sec id="Sec3" sec-type="results">
      <title>Results and discussion</title>
      <p>While on KD the patient continued diazoxide and octreotide treatment (10&#xA0;mg/kg/day and 35 &#x3BC;g/kg/day, respectively). Six months after KD was started, maintenance of blood ketones between 2&#x2013;5&#xA0;mmol/L (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>, panel a) fully resolved neuroglycopenic signs with parallel disappearance of both epileptic crisis and absence epilepsy, despite blood glucose levels permanently below 5.5&#xA0;mmol/L even after meal, and close to 2.2&#x2013;2.7&#xA0;mmol/L most of time (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>, panel b). EEG improved and became normal within the first year on KD, showing no alteration even during episodes of hypoglycemia (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). During the first 6&#xA0;months of KD the patient lost 9&#xA0;kg and her BMI normalized. Psychological evaluation revealed a strengthening of social, cognitive and verbal capacities (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). The child and her family reported an improvement of physical and psychosocial well-being, reduction of fear of hypoglycemic symptoms and awareness of a lower risk of neurological injury, with an overall amelioration of the quality of life related to the management of disease. Diazoxide was discontinued, and currently the patient is given octreotide, reduced to 25 &#x3BC;g/kg/day, without any neuroglycopenic symptoms. KD was well tolerated over a period of 24&#xA0;months, with no side-effects and no changes in laboratory tests.<fig id="Fig1"><label>Fig. 1</label><caption><p>Blood ketones and glucose levels during KD. Ketones progressively raised up to 2&#x2013;5&#xA0;mmol/L while increasing the KD ratio from 1.5:1 to 3:1 (Panel <bold>a</bold>). 120h-continuous glucose monitoring on KD at 2&#xA0;weeks, 3&#xA0;months, 6&#xA0;months, 12&#xA0;months showing persistence of hypoglycemia (mean 52&#xA0;mg/dl, 2.8&#xA0;mmol/L, range 40&#x2013;84&#xA0;mg/dl, 2.2&#x2013;4.6&#xA0;mmol/L) (Panel <bold>b</bold>)</p></caption><graphic xlink:href="13023_2015_342_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Comparison between cerebral activity and glycemia before and after 1&#xA0;year of KD. Disappearance of absence epilepsy or electrical signs despite hypoglycemia. Before KD, long monitoring EEG showed generalized spike and waves discharges with loss of contact during hypoglycemia. On KD, long monitoring EEG appeared normal, with absence of ictal EEG and epileptic manifestations even during hypoglycemia</p></caption><graphic xlink:href="13023_2015_342_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Cognitive an adaptive skills before and after 1&#xA0;year of KD. Normalization of cognitive, social and verbal capacities on KD. Weschsler Intellingence Scale for Children (WISCIII): normal &gt;80, borderline 70&#x2013;80; Vineland Adaptive Behavior Scale (VABS): moderately high 116&#x2013;130, normal 85&#x2013;115, moderately low 70&#x2013;84</p></caption><graphic xlink:href="13023_2015_342_Fig3_HTML" id="MO3"/></fig></p>
      <p>GCK activation caused by gain-of-function mutations determines an increased affinity for glucose and lowers the glucose thresholds for insulin release in the pancreatic beta cell, giving rise to CHI [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR20">20</xref>&#x2013;<xref ref-type="bibr" rid="CR23">23</xref>]. Most patients bearing a <italic>GCK</italic> mutation have relatively mild disease, easily managed with diazoxide, but a few cases with a severe phenotype, who were subjected to near-total pancreatectomy to avoid neurological sequelae, have been described [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Although V455M mutation has been previously associated with a mild phenotype [<xref ref-type="bibr" rid="CR18">18</xref>], our patient displayed a drug-resistant form, with a steep increase of BMI in peripubertal age and a clinical course resembling that described in a patient with the <italic>GCK</italic>/A456V mutation [<xref ref-type="bibr" rid="CR26">26</xref>]. Prompted by patient&#x2019;s long-standing symptoms, drug resistance and the preference of parents to avoid demolitive surgery, we opted for a KD trial to provide an energy source to central nervous system (CNS) alternative to glucose, on the bases of its proven efficacy for the treatment of GLUT1 deficiency [<xref ref-type="bibr" rid="CR14">14</xref>]. We thus challenged the central tenet of treatment of CHI patients, which is to maintain normoglycemia to avoid irreversible brain damage [<xref ref-type="bibr" rid="CR4">4</xref>]. As a matter of fact, neurological sequelae are more prevalent in CHI than in other forms of hypoglycemia because of the inhibition of lipolysis and ketogenesis by inappropriately high insulin levels [<xref ref-type="bibr" rid="CR16">16</xref>]. Ketogenic diet, by restricting the amount of carbohydrates along with a significant increase of fat intake, reproduces a fasting-like condition in which metabolism is shifted from glycolysis to beta-oxidation of FFA and ketone bodies formation for ATP synthesis [<xref ref-type="bibr" rid="CR27">27</xref>]. In our patient we observed that after the beginning of KD neurological symptoms, psychological development and epilepsy manifestations all improved, despite the persistence of hyperinsulinemic hypoglycemia. The neuroprotective effect of ketone bodies has been associated with the activation of a several endogenous metabolic and genetic programs that stabilize and/or enhance cellular metabolism [<xref ref-type="bibr" rid="CR27">27</xref>], increasing cerebral ATP and reducing neuronal excitability. In addition, KD decreases mTOR activity in neuronal cells, thus conferring anticonvulsant effect [<xref ref-type="bibr" rid="CR28">28</xref>]. Of note, KD reverted EEG pathologic patterns in our patient even during hypoglycemia (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). This result highlights the protective effect of KD on CNS despite persistence of neuroglycopenia. Cognitive and adaptive development also improved after the first six months of KD, further confirming its positive effect. Bearing in mind that ketone bodies have additional neuroprotective effects acting as ROS scavengers [<xref ref-type="bibr" rid="CR11">11</xref>], and by inducing PPAR&#x3B1; and UCP2 expression [<xref ref-type="bibr" rid="CR29">29</xref>], and inhibiting glutamate uptake into synaptic vesicles [<xref ref-type="bibr" rid="CR30">30</xref>], we hypothesize that KD might have prolonged positive effects on brain function.</p>
      <p>CNS protective action of 3-hydroxybutyrate has been successfully exploited to treat hypoglycemic coma in rats [<xref ref-type="bibr" rid="CR31">31</xref>] and multiple acyl-CoA dehydrogenase deficiency in humans [<xref ref-type="bibr" rid="CR32">32</xref>]. Consequently, we suggest that the utilization of 3-hydroxybutyrate may be a safer option and an area of investigation in specific patients, such neonates with CHI, in whom administration of KD might be hazardous.</p>
    </sec>
    <sec id="Sec4" sec-type="conclusion">
      <title>Conclusions</title>
      <p>The clinical and neurological improvement observed in our patient with CHI suggests that KD could have a neuroprotective effect despite persistence of neuroglycopenia. Additional studies are needed to confirm the efficacy of this novel therapeutic approach in selected CHI cases to support brain function by providing an alternative energy source to CNS.</p>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>CHI</term>
          <def>
            <p>Congenital hyperinsulinism</p>
          </def>
        </def-item>
        <def-item>
          <term>KD</term>
          <def>
            <p>Ketogenic diet</p>
          </def>
        </def-item>
        <def-item>
          <term>GCK</term>
          <def>
            <p>Glucokinase</p>
          </def>
        </def-item>
        <def-item>
          <term>GLUT1</term>
          <def>
            <p>Glucose transporter 1</p>
          </def>
        </def-item>
        <def-item>
          <term>EEG</term>
          <def>
            <p>Electroencephalography</p>
          </def>
        </def-item>
        <def-item>
          <term>FFA</term>
          <def>
            <p>Free fatty acids</p>
          </def>
        </def-item>
        <def-item>
          <term>ROS</term>
          <def>
            <p>Radical oxygen species </p>
          </def>
        </def-item>
        <def-item>
          <term>CNS</term>
          <def>
            <p>Central nervous system</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Competing interests</bold>
        </p>
        <p>The authors declare that they have no competing interests.</p>
      </fn>
      <fn>
        <p>
          <bold>Authors&#x2019; contributions</bold>
        </p>
        <p>AM conceptualized and designed the study, collected, coordinated and supervised data collection and analysis, drafted the initial manuscript, and approved the final manuscript as submitted. LM contributes to data collection, drafted the initial manuscript, reviewed and revised the manuscript, and approved the final manuscript as submitted. FB carried out genetic analysis, drafted the initial manuscript, critically revised the manuscript and approved the final manuscript as submitted. SB and GG designed the nutritional regimen, drafted the initial manuscript, and approved the final manuscript as submitted. RC performed the neurophysiological studies, drafted the initial manuscript, and approved the final manuscript as submitted. SC performed cognitive evaluation, drafted the initial manuscript, and approved the final manuscript as submitted. CDV conceptualized the study, gave a substantial contribution in data analysis, drafted the initial manuscript, critically reviewed the manuscript and approved the final manuscript as submitted. All authors approved the final manuscript as submitted and agree to be accountable for all aspects of the work. Questions related to the accuracy or integrity of any part of the work were appropriately investigated and resolved from all authors.</p>
      </fn>
    </fn-group>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arnoux</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>de Lonlay</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Ribeiro</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Hussain</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Blankenstein</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Mohnike</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Congenital hyperinsulinism</article-title>
          <source>Early Hum Dev</source>
          <year>2010</year>
          <volume>86</volume>
          <issue>5</issue>
          <fpage>287</fpage>
          <lpage>94</lpage>
          <pub-id pub-id-type="doi">10.1016/j.earlhumdev.2010.05.003</pub-id>
          <pub-id pub-id-type="pmid">20550977</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Hussain</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>De Lonlay</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
          <person-group person-group-type="editor">
            <name>
              <surname>Blau</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Duran</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gibson</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Dionisi-Vici</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>Hyperinsulinism</article-title>
          <source>Physician&#x2019;s Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases</source>
          <year>2014</year>
          <publisher-loc>Berlin Heidelberg</publisher-loc>
          <publisher-name>Springer-Vergal</publisher-name>
          <fpage>323</fpage>
          <lpage>36</lpage>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Buettger</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kwagh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Matter</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Daikhin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Nissim</surname>
              <given-names>IB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A signaling role of glutamine in insulin secretion</article-title>
          <source>J Biol Chem</source>
          <year>2004</year>
          <volume>279</volume>
          <issue>14</issue>
          <fpage>13393</fpage>
          <lpage>401</lpage>
          <pub-id pub-id-type="doi">10.1074/jbc.M311502200</pub-id>
          <pub-id pub-id-type="pmid">14736887</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Menni</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>de Lonlay</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Sevin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Touati</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Peigne</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Barbier</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia</article-title>
          <source>Pediatrics</source>
          <year>2001</year>
          <volume>107</volume>
          <issue>3</issue>
          <fpage>476</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1542/peds.107.3.476</pub-id>
          <pub-id pub-id-type="pmid">11230585</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Auer</surname>
              <given-names>RN</given-names>
            </name>
            <name>
              <surname>Hugh</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cosgrove</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Curry</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
          <article-title>Neuropathologic findings in three cases of profound hypoglycemia</article-title>
          <source>Clin Neuropathol</source>
          <year>1989</year>
          <volume>8</volume>
          <issue>2</issue>
          <fpage>63</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="pmid">2721042</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McNay</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Williamson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>McCrimmon</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Sherwin</surname>
              <given-names>RS</given-names>
            </name>
          </person-group>
          <article-title>Cognitive and neural hippocampal effects of long-term moderate recurrent hypoglycemia</article-title>
          <source>Diabetes</source>
          <year>2006</year>
          <volume>55</volume>
          <issue>4</issue>
          <fpage>1088</fpage>
          <lpage>95</lpage>
          <pub-id pub-id-type="doi">10.2337/diabetes.55.04.06.db05-1314</pub-id>
          <pub-id pub-id-type="pmid">16567533</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamada</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Rensing</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Izumi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>De Erausquin</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Gazit</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Dorsey</surname>
              <given-names>DA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Repetitive hypoglycemia in young rats impairs hippocampal long-term potentiation</article-title>
          <source>Pediatr Res</source>
          <year>2004</year>
          <volume>55</volume>
          <issue>3</issue>
          <fpage>372</fpage>
          <lpage>9</lpage>
          <pub-id pub-id-type="doi">10.1203/01.PDR.0000110523.07240.C1</pub-id>
          <pub-id pub-id-type="pmid">14681492</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ryan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Gurtunca</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Becker</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>Hypoglycemia: a complication of diabetes therapy in children</article-title>
          <source>Pediatr Clin North Am</source>
          <year>2005</year>
          <volume>52</volume>
          <issue>6</issue>
          <fpage>1705</fpage>
          <lpage>33</lpage>
          <pub-id pub-id-type="doi">10.1016/j.pcl.2005.08.002</pub-id>
          <pub-id pub-id-type="pmid">16301090</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blasetti</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chiuri</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Tocco</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Di Giulio</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Mattei</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Ballone</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The effect of recurrent severe hypoglycemia on cognitive performance in children with type 1 diabetes: a meta-analysis</article-title>
          <source>J Child Neurol</source>
          <year>2011</year>
          <volume>26</volume>
          <issue>11</issue>
          <fpage>1383</fpage>
          <lpage>91</lpage>
          <pub-id pub-id-type="doi">10.1177/0883073811406730</pub-id>
          <pub-id pub-id-type="pmid">21572053</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Suh</surname>
              <given-names>SW</given-names>
            </name>
            <name>
              <surname>Hamby</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Swanson</surname>
              <given-names>RA</given-names>
            </name>
          </person-group>
          <article-title>Hypoglycemia, brain energetics, and hypoglycemic neuronal death</article-title>
          <source>Glia</source>
          <year>2007</year>
          <volume>55</volume>
          <issue>12</issue>
          <fpage>1280</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1002/glia.20440</pub-id>
          <pub-id pub-id-type="pmid">17659530</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haces</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Hernandez-Fonseca</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Medina-Campos</surname>
              <given-names>ON</given-names>
            </name>
            <name>
              <surname>Montiel</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Pedraza-Chaverri</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Massieu</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>Antioxidant capacity contributes to protection of ketone bodies against oxidative damage induced during hypoglycemic conditions</article-title>
          <source>Exp Neurol</source>
          <year>2008</year>
          <volume>211</volume>
          <issue>1</issue>
          <fpage>85</fpage>
          <lpage>96</lpage>
          <pub-id pub-id-type="doi">10.1016/j.expneurol.2007.12.029</pub-id>
          <pub-id pub-id-type="pmid">18339375</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yamada</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Rensing</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Thio</surname>
              <given-names>LL</given-names>
            </name>
          </person-group>
          <article-title>Ketogenic diet reduces hypoglycemia-induced neuronal death in young rats</article-title>
          <source>Neurosci Lett</source>
          <year>2005</year>
          <volume>385</volume>
          <issue>3</issue>
          <fpage>210</fpage>
          <lpage>4</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neulet.2005.05.038</pub-id>
          <pub-id pub-id-type="pmid">15975714</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Page</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Williamson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>McNay</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Dzuira</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>McCrimmon</surname>
              <given-names>RJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Medium-chain fatty acids improve cognitive function in intensively treated type 1 diabetic patients and support in vitro synaptic transmission during acute hypoglycemia</article-title>
          <source>Diabetes</source>
          <year>2009</year>
          <volume>58</volume>
          <issue>5</issue>
          <fpage>1237</fpage>
          <lpage>44</lpage>
          <pub-id pub-id-type="doi">10.2337/db08-1557</pub-id>
          <pub-id pub-id-type="pmid">19223595</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Veggiotti</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>De Giorgis</surname>
              <given-names>V</given-names>
            </name>
          </person-group>
          <article-title>Dietary Treatments and New Therapeutic Perspective in GLUT1 Deficiency Syndrome</article-title>
          <source>Curr Treat Options Neurol</source>
          <year>2014</year>
          <volume>16</volume>
          <issue>5</issue>
          <fpage>291</fpage>
          <pub-id pub-id-type="doi">10.1007/s11940-014-0291-8</pub-id>
          <pub-id pub-id-type="pmid">24634059</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pearson</surname>
              <given-names>TS</given-names>
            </name>
            <name>
              <surname>Akman</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Hinton</surname>
              <given-names>VJ</given-names>
            </name>
            <name>
              <surname>Engelstad</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>De Vivo</surname>
              <given-names>DC</given-names>
            </name>
          </person-group>
          <article-title>Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS)</article-title>
          <source>Curr Neurol Neurosci Rep</source>
          <year>2013</year>
          <volume>13</volume>
          <issue>4</issue>
          <fpage>342</fpage>
          <pub-id pub-id-type="doi">10.1007/s11910-013-0342-7</pub-id>
          <pub-id pub-id-type="pmid">23443458</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gataullina</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Dellatolas</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Perdry</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Robert</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Valayannopoulos</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Touati</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comorbidity and metabolic context are crucial factors determining neurological sequelae of hypoglycaemia</article-title>
          <source>Dev Med Child Neurol</source>
          <year>2012</year>
          <volume>54</volume>
          <issue>11</issue>
          <fpage>1012</fpage>
          <lpage>7</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1469-8749.2012.04400.x</pub-id>
          <pub-id pub-id-type="pmid">22924392</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Thornton</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>Stanley</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>De Leon</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Haymond</surname>
              <given-names>MW</given-names>
            </name>
            <name>
              <surname>Hussain</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children</article-title>
          <source>J Pediatr</source>
          <year>2015</year>
          <volume>167</volume>
          <issue>2</issue>
          <fpage>238</fpage>
          <lpage>45</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jpeds.2015.03.057</pub-id>
          <pub-id pub-id-type="pmid">25957977</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Glaser</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Kesavan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Heyman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Cuesta</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Buchs</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Familial hyperinsulinism caused by an activating glucokinase mutation</article-title>
          <source>N Engl J Med</source>
          <year>1998</year>
          <volume>338</volume>
          <issue>4</issue>
          <fpage>226</fpage>
          <lpage>30</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJM199801223380404</pub-id>
          <pub-id pub-id-type="pmid">9435328</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gilbert</surname>
              <given-names>DL</given-names>
            </name>
            <name>
              <surname>Pyzik</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Freeman</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones</article-title>
          <source>J Child Neurol</source>
          <year>2000</year>
          <volume>15</volume>
          <issue>12</issue>
          <fpage>787</fpage>
          <lpage>90</lpage>
          <pub-id pub-id-type="doi">10.1177/088307380001501203</pub-id>
          <pub-id pub-id-type="pmid">11198492</pub-id>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maiorana</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Barbetti</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Boiani</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rufini</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Pizzoferro</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Francalanci</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Focal congenital hyperinsulinism managed by medical treatment: a diagnostic algorithm based on molecular genetic screening</article-title>
          <source>Clin Endocrinol (Oxf)</source>
          <year>2014</year>
          <volume>81</volume>
          <issue>5</issue>
          <fpage>679</fpage>
          <lpage>88</lpage>
          <pub-id pub-id-type="doi">10.1111/cen.12400</pub-id>
          <pub-id pub-id-type="pmid">24383515</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Christesen</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Tribble</surname>
              <given-names>ND</given-names>
            </name>
            <name>
              <surname>Molven</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Siddiqui</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Sandal</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Brusgaard</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation</article-title>
          <source>Eur J Endocrinol</source>
          <year>2008</year>
          <volume>159</volume>
          <issue>1</issue>
          <fpage>27</fpage>
          <lpage>34</lpage>
          <pub-id pub-id-type="doi">10.1530/EJE-08-0203</pub-id>
          <pub-id pub-id-type="pmid">18450771</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Meissner</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Marquard</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cobo-Vuilleumier</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Maringa</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Rodriguez-Bada</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Garcia-Gimeno</surname>
              <given-names>MA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diagnostic difficulties in glucokinase hyperinsulinism</article-title>
          <source>Horm Metab Res</source>
          <year>2009</year>
          <volume>41</volume>
          <issue>4</issue>
          <fpage>320</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.1055/s-0028-1102922</pub-id>
          <pub-id pub-id-type="pmid">19053014</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dullaart</surname>
              <given-names>RP</given-names>
            </name>
            <name>
              <surname>Hoogenberg</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rouwe</surname>
              <given-names>CW</given-names>
            </name>
            <name>
              <surname>Stulp</surname>
              <given-names>BK</given-names>
            </name>
          </person-group>
          <article-title>Family with autosomal dominant hyperinsulinism associated with A456V mutation in the glucokinase gene</article-title>
          <source>J Intern Med</source>
          <year>2004</year>
          <volume>255</volume>
          <issue>1</issue>
          <fpage>143</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.1046/j.0954-6820.2003.01243.x</pub-id>
          <pub-id pub-id-type="pmid">14687251</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sayed</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Langdon</surname>
              <given-names>DR</given-names>
            </name>
            <name>
              <surname>Odili</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Buettger</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Schiffman</surname>
              <given-names>AB</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations</article-title>
          <source>Diabetes</source>
          <year>2009</year>
          <volume>58</volume>
          <issue>6</issue>
          <fpage>1419</fpage>
          <lpage>27</lpage>
          <pub-id pub-id-type="doi">10.2337/db08-1792</pub-id>
          <pub-id pub-id-type="pmid">19336674</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cuesta-Munoz</surname>
              <given-names>AL</given-names>
            </name>
            <name>
              <surname>Huopio</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Otonkoski</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Gomez-Zumaquero</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Nanto-Salonen</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Rahier</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation</article-title>
          <source>Diabetes</source>
          <year>2004</year>
          <volume>53</volume>
          <issue>8</issue>
          <fpage>2164</fpage>
          <lpage>8</lpage>
          <pub-id pub-id-type="doi">10.2337/diabetes.53.8.2164</pub-id>
          <pub-id pub-id-type="pmid">15277402</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Christesen</surname>
              <given-names>HB</given-names>
            </name>
            <name>
              <surname>Jacobsen</surname>
              <given-names>BB</given-names>
            </name>
            <name>
              <surname>Odili</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Buettger</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cuesta-Munoz</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy</article-title>
          <source>Diabetes</source>
          <year>2002</year>
          <volume>51</volume>
          <issue>4</issue>
          <fpage>1240</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="doi">10.2337/diabetes.51.4.1240</pub-id>
          <pub-id pub-id-type="pmid">11916951</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bough</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Rho</surname>
              <given-names>JM</given-names>
            </name>
          </person-group>
          <article-title>Anticonvulsant mechanisms of the ketogenic diet</article-title>
          <source>Epilepsia</source>
          <year>2007</year>
          <volume>48</volume>
          <issue>1</issue>
          <fpage>43</fpage>
          <lpage>58</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1528-1167.2007.00915.x</pub-id>
          <pub-id pub-id-type="pmid">17241207</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>McDaniel</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Rensing</surname>
              <given-names>NR</given-names>
            </name>
            <name>
              <surname>Thio</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Yamada</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>The ketogenic diet inhibits the mammalian target of rapamycin (mTOR) pathway</article-title>
          <source>Epilepsia</source>
          <year>2011</year>
          <volume>52</volume>
          <issue>3</issue>
          <fpage>e7</fpage>
          <lpage>11</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1528-1167.2011.02981.x</pub-id>
          <pub-id pub-id-type="pmid">21371020</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Diano</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Matthews</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Patrylo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Beal</surname>
              <given-names>MF</given-names>
            </name>
            <name>
              <surname>Barnstable</surname>
              <given-names>CJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Uncoupling protein 2 prevents neuronal death including that occurring during seizures: a mechanism for preconditioning</article-title>
          <source>Endocrinology</source>
          <year>2003</year>
          <volume>144</volume>
          <issue>11</issue>
          <fpage>5014</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="doi">10.1210/en.2003-0667</pub-id>
          <pub-id pub-id-type="pmid">12960023</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Juge</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Gray</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Omote</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Miyaji</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Inoue</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hara</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Metabolic control of vesicular glutamate transport and release</article-title>
          <source>Neuron</source>
          <year>2010</year>
          <volume>68</volume>
          <issue>1</issue>
          <fpage>99</fpage>
          <lpage>112</lpage>
          <pub-id pub-id-type="doi">10.1016/j.neuron.2010.09.002</pub-id>
          <pub-id pub-id-type="pmid">20920794</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schutz</surname>
              <given-names>PW</given-names>
            </name>
            <name>
              <surname>Struys</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Sinclair</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Stockler</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Protective effects of d-3-hydroxybutyrate and propionate during hypoglycemic coma: clinical and biochemical insights from infant rats</article-title>
          <source>Mol Genet Metab</source>
          <year>2011</year>
          <volume>103</volume>
          <issue>2</issue>
          <fpage>179</fpage>
          <lpage>84</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ymgme.2011.02.015</pub-id>
          <pub-id pub-id-type="pmid">21439874</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van Hove</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Grunewald</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jaeken</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Demaerel</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Declercq</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Bourdoux</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>D, L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD)</article-title>
          <source>Lancet</source>
          <year>2003</year>
          <volume>361</volume>
          <issue>9367</issue>
          <fpage>1433</fpage>
          <lpage>5</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(03)13105-4</pub-id>
          <pub-id pub-id-type="pmid">12727399</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
